SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis

J. Daniel Kelly(University of California, San Francisco), Tristan Curteis(Costello Medical Consulting (United Kingdom)), Aaditya Rawal, Molly Murton(Costello Medical Consulting (United Kingdom)), Laura J. Clark(Costello Medical Consulting (United Kingdom)), Zarena Jafry, Rikisha Shah-Gupta(Gilead Sciences (United Kingdom)), Mark Berry(Gilead Sciences (United Kingdom)), Aprille Espinueva(Gilead Sciences (United States)), Linda Chen(Gilead Sciences (United States)), Mazin Abdelghany(Gilead Sciences (United States)), Daniel A. Sweeney(University of California System), Jennifer K Quint(Imperial College London)
European Respiratory Review
July 12, 2023
Cited by 31Open Access
Full Text

Abstract

BACKGROUND: Many individuals hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection experience post-acute sequelae of SARS-CoV-2 infection (PASC), sometimes referred to as "long COVID". Our objective was to conduct a systematic literature review and meta-analysis to identify PASC-associated symptoms in previously hospitalised patients and determine the frequency and temporal nature of PASC. METHODS: Searches of MEDLINE, Embase, Cochrane Library (2019-2021), World Health Organization International Clinical Trials Registry Platform and reference lists were performed from November to December 2021. Articles were assessed by two reviewers against eligibility criteria and a risk of bias tool. Symptom data were synthesised by random effects meta-analyses. RESULTS: Of 6942 records, 52 studies with at least 100 patients were analysed; ∼70% were Europe-based studies. Most data were from the first wave of the pandemic. PASC symptoms were analysed from 28 days after hospital discharge. At 1-4 months post-acute SARS-CoV-2 infection, the most frequent individual symptoms were fatigue (29.3% (95% CI 20.1-40.6%)) and dyspnoea (19.6% (95% CI 12.8-28.7%)). Many patients experienced at least one symptom at 4-8 months (73.1% (95% CI 44.2-90.3%)) and 8-12 months (75.0% (95% CI 56.4-87.4%)). CONCLUSIONS: A wide spectrum of persistent PASC-associated symptoms were reported over the 1-year follow-up period in a significant proportion of participants. Further research is needed to better define PASC duration and determine whether factors such as disease severity, vaccination and treatments have an impact on PASC.


Related Papers